14th Annual Meeting of the Korean Society of Medical Oncology & 2021 International Conference

Curriculum Vitae

Name	Sue Yom	
Current Position & Affiliation	Vice Chair and Jacobs Distinguished Professor, UCSF	
Country	USA	

Educational Background

University of Pennsylvania, School of Medicine – 2007 M.D. Anderson Cancer Center, Residency in Radiation Oncology – 2007

Professional Experience

Vice Chair and Professor, Department of Radiation Oncology, UCSF Professor by courtesy, Department of Otolaryngology-Head and Neck Surgery, UCSF

Professional Organizations

American Radium Society (ARS) – President, 2020-2021 American Society of Radiation Oncology (ASTRO) American Head and Neck Society (AHNS)

Main Scientific Publications

1. Yom SS, Liao Z, Liu H, Liu HH, Tucker SL, Hu C-S, Wei X, Wang X, Wang S, Mohan R, Cox JD, Komaki R. Initial Evaluation of Treatment-Related Pneumonitis in Advanced-Stage Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemotherapy and Intensity-Modulated Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics 2007;68(1):94-102.

This article was the first to describe the use of IMRT in lung cancer and describe dosimetric principles for avoiding complications. It remains a standard reference in the lung cancer radiotherapy field.



- Ouyang D, El-Sayed IH, Yom SS. National trends in surgery for sinonasal malignancy and the effect of hospital volume on short-term outcomes. Laryngoscope. 2014 Jul;124(7):1609-14. doi: 10.1002/lary.24578. Epub 2014 Feb 10.
 - This project was developed by one of my students under my direct supervision. We developed a population-derived database and analyzed the impact of hospital volume on outcomes of sinonasal surgery. This is the first such study of the relationship of patient volume and outcomes in this disease site.
- 3. Chyan A, Chen J, Shugard E, Lambert L, Quivey JM, Yom SS. Dosimetric predictors of hypothyroidism in oropharyngeal cancer patients treated with intensity-modulated radiation therapy. Radiat Oncol. 2014 Dec 5;9:269. doi: 10.1186/s13014-014-0269-4.
 - This study was developed by a medical student and one of our (then junior) physicists as a clinical-physics translation project under my direction. It was noticed and cited as one of best papers examining the effects of radiotherapy on thyroid function.
- 4. Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Foote RL, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian N, Hughes M. Head and Neck Cancers, Version 1.2015. J Natl Compr Canc Netw. 2015 Jul;13(7):847-56.
 - I have a longstanding interest in development of practice guidelines. I served as a writing member for this NCCN Insight explaining changes in the national standard of head and neck cancer radiotherapy and stance of the NCCN panel on the use of particle therapies.
- 5. Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, Gillison ML, Jordan RC, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014 Sep 20;32(27):2940-50.
 - This is a national cooperative group study in which I participated. The data from this study has shaped the national cooperative group approach to HPV-associated oropharyngeal cancer and I am now the current national PI on the study addressing this disease.